How the Plan Works
The subscription model is an innovative drug pricing and payment mechanism to enable Louisiana to dramatically expand access to Hepatitis C treatment within its Medicaid and incarcerated populations. Louisiana selected Asegua Therapeutics, a subsidiary of Gilead Sciences, Inc., as its pharmaceutical partner.
Asegua will provide unrestricted access to the authorized generic for Epclusa for Medicaid eligible and incarcerated Louisianans for 5 years. Our goal is to cure at least 10,000 Medicaid-enrolled and incarcerated individuals per year.
Training & Resources
If you’re a provider of treatment or would like to be a provider, learn more about the LDH initiative here.
One Hour HCV Webinar
Take our one hour HCV webinar for CME credit to learn about HCV infection, epidemiology, staging and treatment.
Complete this form to register and the webinar link will be emailed to you.